MAPT and dementia: We first analysed neurodegeneration patterns across four biomarker groups: 60 controls (A−T−&CU; amyloid negative, tau negative, cognitively unimpaired), 25 A+T− (amyloid positive, tau negative), 121 A+T+ (amyloid positive, tau positive) and 100 other dementia (A−T−&CI; amyloid negative, tau negative, cognitively impaired).